Charged Alpha Stock Encyclopedia

Phibro Animal Health (PAHC) Q4 FY2026 — FY2026 (year ended June 30, 2026): net sales $1,518.1m vs $1,296.2m, up 17.1%; adjusted EBITDA $255.0m vs $183.7m, up 38.8%; adjusted diluted EPS $3.22 vs $2.17; GAAP diluted EPS $2.43. Q4 adjusted EPS $0.85 against a $0.71 bar, a 19% beat, on sales of $396.7m. Free cash flow $9.9m. The stock opened +9.1% at $39.39 on August 27, traded to $35.01 and closed $36.35, up 0.72% on 432,907 shares, 2.4x its 30-session median.
Phibro filed its 10-K at 16:14 Eastern on August 26 and the results 8-K at 16:30, both just after the close, and the stock opened up 9.1% the next morning before closing up 0.72%. Nearly the whole gap was given back in one session. The record is real: net sales $1,518.1m, adjusted EBITDA $255.0m up 38.8%, adjusted EPS $3.22 against a $0.71 fourth-quarter bar it beat by 19%, and FY2027 guidance that came in 5.4% ABOVE the published consensus rather than below it. But $146.1m of the $221.9m sales increase is the company's own disclosed incremental revenue from the Zoetis MFA portfolio, which closed October 31, 2024 - four extra months on a calendar. And $255.0m of adjusted EBITDA produced $9.9m of free cash flow.
THE CALL: HOLD (3/5, A REAL BEAT AND A REAL RECORD YEAR THAT CONVERTED ALMOST NONE OF ITSELF INTO CASH) — base-case value ~$37.03 vs ~$36.35 today.
KEY METRICS:
- THE SPINE: $255.0m of adjusted EBITDA produced $9.9m of free cash flow - 3.9% conversion, against 22.8% the year before.
- SAME TWELVE MONTHS: adjusted EBITDA rose $71.3m while operating cash flow FELL $11.2m, from $80.1m to $69.0m.
- WHERE IT WENT: working capital absorbed $95.1m, $86.3m of it inventory. Capex rose 54% to $59.1m against $51.5m of D&A.
- THE GROWTH: $146.1m of the $221.9m sales increase is disclosed incremental Zoetis MFA revenue - four extra months of a deal that closed Oct 31, 2024.
- ONCE LAPPED: in Q4, with both years carrying a full acquisition, MFAs grew $1.1m on $206.5m. Mineral Nutrition was 71% of the quarterly increase.
- THE CONCESSION: the beat is real on the proven adjusted basis, guidance came in 5.4% above consensus, and Animal Health margin expanded 303bp.
- THE GUIDE: FY2027 adjusted EBITDA +3.1%, but adjusted EPS +8.7% - and 58% of that earnings growth is the tax rate going 23.7% to about 20%.
- OUR CALL: HOLD, 3/5, fair value $37.03 vs $36.35. Bear $27.81, base $38.90, bull $48.19. Street average $45.00 across five analysts.
What to watch: UP: the Q4 beat is real on the proven basis - $0.85 against $0.713, with sales 4.1% ahead; FY2027 adjusted EPS guidance of $3.41-$3.59 is 5.4% above the $3.32 consensus; Animal Health adjusted EBITDA margin expanded 303bp to 26.1%; Brazil virginiamycin, about $27m of FY2026 sales, is already assumed at near zero in guidance, so registration is unbooked upside; Phibro Forward closed June 30 and management traces nearly one in five guided EBITDA dollars to it; gross leverage 2.9x and no large maturity until $406.6m in FY2030. DOWN: free cash flow $9.9m against $255.0m of adjusted EBITDA, a 3.9% conversion versus 22.8%; operating cash flow FELL $11.2m to $69.0m while adjusted EBITDA rose $71.3m; working capital took $95.1m, of which inventory was $86.3m; inventory $534.9m is 194 days of COGS against 181; capex +54% to $59.1m; the dividend cost $19.5m, twice free cash flow; guidance is +3.1% EBITDA growth and assumes zero FX losses after $12.6m.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Build-A-Bear Workshop, Inc. (BBW) Q2 FY2026 — Q2 FY2026 (thirteen weeks ended August 1, 2026): revenue $115.291m vs $124.247m, -7.2%; e-commerce demand -15.6%; gross margin 54.2% vs 57.6%; pre-tax income $11.631m vs $15.318m; diluted EPS $0.70 vs $0.94 against a $0.645 bar, so it BEAT. The shares gapped -14.99% and closed $28.44, -27.26%, on 14.8x the twelve-month median volume.
Build-A-Bear Workshop BEAT its earnings bar - $0.70 against $0.645 - and fell 27.26%, its worst session in a year. What was repriced was not the quarter, it was the plan: in May commercial (wholesale) revenue was guided to grow at least 20% this year, and on August 27 it was guided flat, the Chief Growth Officer was terminated in the same 8-K, and the full-year outlook was cut for the second time in three months.
THE CALL: HOLD (3/5, A DEBT-FREE BRAND ON EIGHT TIMES ITS OWN GUIDANCE, WITH ITS GROWTH LEG GUIDED TO ZERO) — base-case value ~$32.30 vs ~$28.44 today.
KEY METRICS:
- THE STREET AND THE CALL: NOT ONE sell-side target was struck after this print. Two could be sourced AND dated - D.A. Davidson Buy $60 (May 29, 2026) and Northland Outperform $80 (Aug 29, 2025). We value BBW at $32.30 vs $28.44 on three methods spanning 1.08x: DCF $30.76, owner earnings $32.95, EV/EBITDA $33.21. HOLD, 3/5. Bull $44.78, bear $21.71.
- THE SPINE: revenue fell $8.956m and cost of merchandise sold ROSE $0.066m, because store occupancy is reported INSIDE that line. Gross profit fell $9.022m - 100.7% of the entire sales decline landed in profit. Gross margin 57.6% to 54.2%, while SG&A actually LEVERAGED 80bp.
- THE GROWTH LEG INVERTED IN ONE QUARTER: commercial (wholesale) revenue was +43.6% in Q1 ($7.622m to $10.948m) and -6.3% in Q2 ($8.629m to $8.086m). The CEO: 'certain wholesale opportunities may take longer to realize than previously anticipated.'
- SO THE GUIDE REMOVED IT: 'commercial revenue growth of AT LEAST 20%' in May became 'approximately flat' in August - $7.75m out of the plan on last year's $38.750m, and an implied second half 12.4% BELOW last year's.
- AND THE CHIEF GROWTH OFFICER WENT WITH IT, IN THE SAME 8-K. Item 5.02: David Henderson terminated WITHOUT CAUSE on August 26, the day before the print. The role was created June 11, 2026 - 76 days earlier - at the CEO handover. Severance $501,500. We label the link an inference, not a proof.
- THE YEAR HAS BEEN CUT TWICE IN THREE MONTHS: revenue mid-single-digit GROWTH in March, $530m-$550m in May, $500m-$525m now; adjusted pre-tax $65m-$71m became $53m-$61m. The TOP of the new revenue range, $525m, sits BELOW fiscal 2025's $529.832m: the five-year record streak ends.
- READ THE 'BACK-HALF WEIGHTED' YEAR AS ARITHMETIC: H1 adjusted pre-tax was $28.5m, so the guide implies $24.5m-$32.5m for H2 against $32.3m last year. The TOP of the range merely MATCHES last year - and still contains about $6m of IEEPA tariff refund.
What to watch: UP: it beat the bar; no borrowings; 8.2x its own adjusted guidance and a 3.23% dividend; 44% of the 674-location fleet is partner-operated or franchised. DOWN: revenue -7.2% while cost of merchandise sold ROSE, so 100.7% of the sales decline landed in profit; the revenue guide now tops out BELOW fiscal 2025's record; cash -64% to $14.0m.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Standard Nuclear (STDN) Q2 2026 — Q2 2026 (three months ended June 30, 2026): total revenue $4.74m vs $0.55m, up 756%; product revenue $3.10m from the first commercial TRISO delivery; gross profit $3.18m, a 67.2% margin and the first ever; G&A $5.52m, R&D $1.96m; operating loss $4.30m; net loss $3.42m, $(0.12) per share on 28.0m pre-IPO shares. The stock closed $14.31 on August 27, up 4.45% on 796,970 shares.
Standard Nuclear filed its results in an Item 2.02 8-K at 20:26 Eastern on August 26 - an exhibit EDGAR's own index does not list - with the 10-Q following at 08:09 the next morning. The stock opened just 1.0% higher, traded below its prior close, and finished at $14.31, its high of the day and its best close since the July 16 listing. The quarter is the first with a product in it: 50 kgU of TRISO delivered to Radiant for $3.10m, the first complete reactor core of commercially produced TRISO from an independent US maker. It is also the first time this backlog has a price per kilogram behind it.
THE CALL: BEARISH (3/5, A REAL FIRST DELIVERY AND A PRICE THAT ALREADY NEEDS MORE PLANTS THAN HAVE BEEN ANNOUNCED) — base-case value ~$8.64 vs ~$14.31 today.
KEY METRICS:
- THE SPINE: the first delivery prices TRISO. 50 kgU for $3.10m is $62,000/kgU - the first observable price this company has printed.
- CROSS-CHECK: the Antares firm one-ton commitment lifted Funded Backlog 93% to $119.3m. That $57.4m for one MTU is $57,400/kgU.
- THIRD ROUTE: the seven-ton option added $287.0m to Purchase Options, or $41,000/kgU. Three routes, spanning just 1.51x.
- THE CEILING: every announced plant fully ramped is 6.83 MTU a year, or $392m of revenue. The enterprise value is $2.00bn - 5.1x that.
- THE REVERSE TEST: at 12% over 5 years to a 20x terminal on a 25% margin, $2.00bn needs $705m of revenue - 12.3 MTU, 1.8x the whole plan.
- THE CAVEAT: only 21% of the $576.9m backlog binds. The release itself says it is not a measure of contracted revenue.
- THE CONCESSION: first ever gross profit $3.18m at 67.2%, backlog up six-fold since March, $239.9m of cash and no debt at all.
- OUR CALL: BEARISH, 3/5, fair value $8.64 vs $14.31. Bear $2.38, base $8.16, bull $15.88. Six targets, all dated August 10, average $15.50.
What to watch: UP: revenue $4.74m from $0.55m; first gross profit $3.18m at 67.2%; Total Contract Backlog $91.3m to $576.9m since March; Funded Backlog $8.2m to $119.3m; $239.9m pro forma cash, no debt, total liabilities $9.5m; construction substantially complete at both new plants; DOE approved the preliminary safety analysis for each. DOWN: the six-month column still shows a $1.23m gross LOSS; only 21% of the headline backlog binds and 77% is unexercised options; free cash outflow $28.4m in six months; neither new plant is authorised to operate; two customers were 89% of the quarter; the stock has never closed above its $15.00 IPO price.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Mesoblast (MESO) FY2026 — FY2026 (twelve months ended June 30, 2026): total revenue $120.25m vs $17.2m, up 599.2%; net Ryoncil product sales $115.2m vs $11.3m; gross profit ex-amortisation $109.7m, a 91.2% margin; R&D $97.5m vs $34.8m; SG&A $57.3m vs $39.3m; reported loss $57.5m vs $102.1m; loss per ADS $0.444. The ADS closed $18.18 on August 27, up 7.96% on 541,633 shares, 3.0x its 30-session median.
Mesoblast filed its audited 20-F at 06:08 Eastern on August 27 and the results 6-K at 07:09, both before the open, and the stock closed up 7.96% on three times median volume. The launch is real: Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, did $115.2m of net product sales in its first full year, the second half out-earned the first by 34.2%, and the fourth quarter alone did $36m. The release leads with a loss cut 44% to $57.5m. But $32.8m of that $44.6m improvement - 73.4% - is the swing in two non-cash fair value lines. Strip them and $103.1m of new revenue bought $11.9m of loss reduction.
THE CALL: BEARISH (3/5, A GENUINELY GOOD FIRST LAUNCH YEAR THAT IS NOT WHAT THE SHARE PRICE IS PAYING FOR) — base-case value ~$14.28 vs ~$18.18 today.
KEY METRICS:
- THE SPINE: the reported loss narrowed $44.6m, but $32.8m of that - 73.4% - is two non-cash fair value marks, not the business.
- EX-MARKS: the underlying loss went $82.3m to $70.4m. So $103.1m of new revenue bought $11.9m of improvement - 11.5% drop-through.
- THE MARKS: contingent consideration swung from a $14.9m charge to a $12.1m gain; the warrant liability from a $5.0m charge to a gain.
- THE CASH: $88.4m received against $120.25m booked. Receivables $14.9m to $57.7m, 175 days, and one customer is the entire product book.
- THE BALANCE SHEET: intangibles $566.4m are 99.6% of $568.4m net assets. Borrowings $119.2m vs $102.9m cash - net debt, in year one.
- THE CONCESSION: second-half revenue $68.9m vs $51.3m, +34.2%. Q4 product sales $36m annualise to $144m. 50 centres, 280m covered lives.
- WHAT YOU PAY FOR: our approved franchise is $9.87 an ADS. The tape is $18.18, so $8.31 - 46% - is six unapproved programmes.
- OUR CALL: BEARISH, 3/5, fair value $14.28 vs $18.18. Bear $7.28, base $14.16, bull $21.51. Two April targets, both $35.00.
What to watch: UP: revenue $120.25m beat the $117.5m seven-analyst consensus by 2.3%; second-half revenue $68.9m against a $51.3m first half; Q4 product sales $36m annualise to $144m; operating cash outflow only $13.4m in the second half; gross-to-net 13.4% against 14.6%; 50+ transplant centres including 14 of the 15 largest; 280m covered lives; time to treatment 29 days to 8. DOWN: cash receipts $88.4m against $120.25m of revenue; receivables $14.9m to $57.7m, 175 days, and the 20-F says one single external customer is the whole product book; intangibles $566.4m are 99.6% of net assets; borrowings $119.2m against $102.9m of cash is net debt; finance costs $23.8m are 19.8% of revenue.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Super Hi (HDL) Q2 2026 — Q2 2026 (three months ended June 30, 2026): revenue $218.8m vs $198.9m, up 10.0%; Haidilao restaurant revenue $197.8m, up 4.6%; same-store sales $179.4m vs $180.9m, down 0.8%; income from operation $8.1m vs $3.7m, margin 3.7% vs 1.9%; loss for the period $1.9m against a $16.4m profit. The 9658 ordinary line fell 6.93% on August 27 on 1,745,400 shares; the ADS closed $13.275, down 6.05% on 1,157 shares.
Super Hi International, which operates the Haidilao hot pot restaurants outside China, reported Q2 2026 at 07:00 Eastern on August 26: revenue $218.8m, up 10.0%, and an operating measure the company defines itself that more than doubled to $8.1m. Five pages later the same release prints the same-store table. Across the 111 restaurants open through both quarters, sales fell 0.8% - $179.4m against $180.9m - after rising 1.7% across the full half. The comparison rolled over inside the half.
THE CALL: BEARISH (3/5, A REAL MARGIN GAIN ON A DEMAND LINE THAT TURNED NEGATIVE INSIDE THE HALF) — base-case value ~$10.88 vs ~$13.275 today.
KEY METRICS:
- THE SPINE: revenue +10.0%, Haidilao restaurant revenue +4.6%, and same-store sales -0.8%. Each layer is smaller than the one above it.
- THE MIX: delivery $7.6m (+105.4%) and condiments $13.4m (+119.7%) added $11.2m of the $19.9m the group added. The restaurants added $8.7m.
- NO PRICING: average spend per guest was $24.30 in both quarters. Guest visits rose 5.2% to 8.1m. All of the growth is volume and mix.
- NORTH AMERICA: same-store sales -8.5%, table turnover 4.0 to 3.6 turns a day, spend per guest $41.00 from $39.10. Fewer guests, higher ticket.
- THE CONCESSION: restaurant level margin 6.4% to 10.7% over the half, +430bp, and income from operation $11.8m to $22.1m, up 86.7%. Real.
- THE LOSS: a $20.6m currency swing and $4.7m of tax on $2.8m of pre-tax profit made it a $1.9m loss. There is no hedging policy at all.
- THE CASH: $269.9m of cash and no borrowings, but $234.4m of leases take about $56.2m a year out below operating cash flow.
- OUR CALL: BEARISH, 3/5, fair value $10.88 vs $13.28. Bear $8.54, base $11.30, bull $15.87. Five Hong Kong analysts average $18.45 an ADS.
What to watch: UP: restaurant level operating margin went from 6.4% to 10.7% across the half, a 430 basis point gain, and restaurant level profit rose from $24.8m to $44.4m. Staff cost fell to 34.3% of revenue from 35.3%. There are no bank borrowings and cash plus pledged deposits of $269.9m is 31.3% of the market value. DOWN: same-store sales are negative, North American comps fell 8.5% with table turnover down from 4.0 to 3.6 turns a day, average daily revenue per restaurant fell to $17.4k from $17.6k, and 56.3% of the quarter's growth came from delivery and condiments, which are 9.6% of sales.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Formula Systems (FORTY) Q2 2026 — Q2 2026 (three months ended June 30, 2026): revenue $782.4m vs $602.7m, up 29.8%; gross margin 20.2% vs 20.4%; operating profit $71.6m, up 41.3%, margin 9.2% vs 8.4%; group continuing profit $51.6m of which 54.9% is minority; attributable $23.3m vs $8.8m; diluted continuing EPS $1.47 vs $0.56. Shares closed August 25 at $117.51, up 1.96% on 608 shares, and $121.36 on August 26.
Formula Systems reported Q2 2026 before the open on August 25: revenue $782.4m, up 29.8% to a second-quarter record, and diluted continuing EPS of $1.47 against $0.56. Both comparisons are like-for-like - the 2025 columns were restated under IFRS 5 with Sapiens as discontinued operations. But Formula earns in shekels and reports in dollars, and the average rate went from 3.5719 to 2.9511 across the same three months. At last year's rate this quarter is $646.5m, or +7.3% - close to the +6.3% Matrix reported in its own currency.
THE CALL: HOLD (3/5, A REAL RECORD ON A CURRENCY TAILWIND, AND AN ASSET DISCOUNT WITH NO CATALYST) — base-case value ~$128.30 vs ~$121.36 today.
KEY METRICS:
- THE SPINE: revenue +29.8% reported, but the dollar bought 3.5719 shekels in Q2 2025 and 2.9511 in Q2 2026. At last year's rate: $646.5m, or +7.3%.
- THE CROSS-CHECK: Matrix is 91.8% of group revenue and reported +6.3% in shekels. Two routes to the same constant-currency answer.
- THE OTHER HALF: attributable profit $8.8m to $23.3m. Formula's slice of group profit went 30.5% to 45.1% - worth $7.6m; growth gave $6.9m.
- WHY THE SLICE MOVED: net financial expense halved, $11.1m to $5.6m, on interest earned at the parent where there are no minorities.
- THE CONCESSION: operating profit $71.6m up 41.3%, margin 9.2% from 8.4% - up 74bp on cost lines 94bp lower. Currency cancels out of a ratio.
- THE ASSET: Matrix closed at NIS 99.92 on 92.54m shares = $3.12bn. The filed 47.68% is $1.49bn against a $1.86bn value for all of Formula.
- THE DISCOUNT: net asset value $154.46 vs a $121.36 tape, 21.4% off. The market implies $980.2m for the Matrix stake, 34.1% below its quote.
- OUR CALL: HOLD, 3/5, fair value $128.30 vs $121.36. Bear $101.28, bull $149.35. No sell-side board: four vendor endpoints return empty.
What to watch: UP: at constant currency the group still grew 7.3% and the operating margin widened 74 basis points, which currency cannot explain because costs are earned in shekels too. Net financial debt to capitalisation is negative 27.08% against a 65% covenant. And Formula's filed 47.68% of Tel Aviv listed Matrix is worth $1.49bn against a $1.86bn market value for the whole company. DOWN: a shekel reversal takes reported dollar revenue down about a fifth with no operational change. Formula keeps only 45.1% of group profit, the holding-company discount has no mechanism to close, and 608 shares moved on results day.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Strattec Security Corporation (STRT) Q4 FY2026 — Fiscal Q4 and FY2026 (periods ended June 28, 2026): Q4 sales $151.8m vs $152.0m; Q4 gross margin 15.6% vs 16.7%; Q4 profit from operations $6.2m, down 27.5%; Q4 adjusted EBITDA $12.5m vs $13.0m; Q4 adjusted EPS $2.06, identical to a year earlier, against a $1.36 estimate; Q4 GAAP EPS $0.95 vs $2.01. FY sales $579.4m, up 2.5%; FY adjusted EBITDA $50.5m, up 15.3%. Shares closed August 26 at $72.76, down 7.98% from $79.07 on 274,608 shares, 3.4x the 30-day median.
Strattec Security reported fiscal Q4 and full-year 2026 adjusted EPS of $2.06 against a $1.36 estimate - a 51% beat - and the stock fell 7.98% the next session. Two things explain it. First, that $2.06 is EXACTLY what the company earned on the same adjusted basis a year earlier, to the cent, while profit from operations fell 27.5%. Second, the company's own per-quarter reconciliation shows the full-year improvement was entirely a first-half event: profit from operations ran +$5.4m and +$2.7m against the prior year in the September and December quarters, then -$2.0m and -$2.3m in March and June. The first half added $8.1m; the second half gave $4.4m back; the whole year gained $3.7m.
THE CALL: HOLD (3/5, A GENUINELY BETTER YEAR WHOSE ENTIRE IMPROVEMENT WAS EARNED IN THE FIRST HALF) — base-case value ~$75.99 vs ~$72.76 today.
KEY METRICS:
- THE SPINE: profit from operations against the prior-year quarter ran +$5.4m, +$2.7m, then -$2.0m and -$2.3m. First half +$8.1m, second half -$4.4m, full year +$3.7m.
- THE EXIT RATE: adjusted EBITDA by fiscal 2026 quarter $15.6m, $12.3m, $10.1m, $12.5m. Margin 10.2% to 8.3%, under the 8.5% of the year-ago quarter.
- THE BEAT: adjusted EPS $2.06 vs a $1.36 estimate is +51%. It is also identical to the $2.06 of a year earlier. GAAP EPS was $0.95 vs $2.01.
- THE TAX: Q4 effective rate 62.4% vs 21.2%. Pre-tax profit fell only 6% but tax expense rose to $6.0m, and a $2.4m discrete tax item is 53% of the whole GAAP-to-adjusted bridge.
- THE YEAR, CONCEDED: sales $579.4m up 2.5%, gross margin 16.5% wider by 149 basis points, adjusted EBITDA $50.5m up 15.3%, adjusted EPS $6.88 vs $5.38.
- THE BALANCE SHEET: $108.2m cash, $0.0m borrowings, enterprise value $208.0m = 4.12x. Free cash flow $39.0m = $9.80 a share, a 13.5% yield.
- BASIS PROVED: all four filed quarters sum exactly to the filed year on sales, operating profit, adjusted EBITDA and both earnings measures.
- OUR CALL: HOLD, 3/5, fair value $75.99 vs $72.76. Bear $63.45, base $77.03, bull $86.46. The only sourced Street target is $89.00, set 107 days before this print.
What to watch: UP: fiscal 2026 was genuinely better - sales $579.4m up 2.5%, gross margin 16.5% wider by 149 basis points, adjusted EBITDA $50.5m up 15.3%. ZERO borrowings after repaying $8.0m, and $108.2m of cash - $27.21 a share, 37% of the price - leaving an enterprise value of $208.0m, or 4.12x. Free cash flow $39.0m, $9.80 a share, a 13.5% yield, and clean: working capital added just +$0.5m against +$37.5m last year. The board bought $7.4m of stock at $67.10 and authorised a new $40.0m programme. DOWN: the exit quarter margin of 8.3% is below the 10.2% the year opened with AND the 8.5% of the year-ago quarter; the second half annualises at $45.3m against a $50.5m year; fiscal 2027 was guided with the three largest customers down ~6% and a peso move worth ~100 basis points of gross margin; capital spending ran at 49% of depreciation.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Tuya Inc. (TUYA) Q2 2026 — Q2 2026 (three months ended June 30, 2026): revenue $92.9m, up 16.0%; net profit $18.6m, up 48.0%; non-GAAP net profit $18.9m, DOWN 5.8%; EPS $0.03 per ADS on both a GAAP and a non-GAAP basis, in line with a $0.03 bar; gross margin 46.3% vs 48.4%; operating cash flow $6.2m vs $18.2m. Shares closed August 25 at $1.79, up 1.70% from $1.76 on 1,721,865 shares.
Tuya Inc. reported net profit of $18.6m for the June quarter, up 48.0% from $12.6m, on revenue of $92.9m, up 16.0%. The stock closed up just 1.70%. The reason is in the company's own non-GAAP reconciliation. Tuya defines non-GAAP profit by adding back share-based compensation - and that expense collapsed 92.0%, from $7.479m to $0.602m, as equity awards granted at 2021 IPO valuations finished amortising. On the company's OWN non-GAAP measure, net profit FELL 5.8%, from $20.1m to $18.9m. The $6.877m fall in stock compensation is 84% of the entire $8.220m rise in operating profit. And of the pre-tax profit that remains, financial income of $10.556m - interest on a $976.1m cash pile - exceeded the $9.308m the whole operating business earned.
THE CALL: HOLD (3/5, A HEADLINE PROFIT JUMP THAT WAS AN AMORTISATION SCHEDULE EXPIRING) — base-case value ~$1.94 vs ~$1.79 today.
KEY METRICS:
- THE SPINE: GAAP net profit rose 48.0% to $18.6m, but the company's OWN non-GAAP net profit FELL 5.8%, $20.1m to $18.9m. Same quarter, same filing.
- THE CAUSE: share-based compensation fell 92.0%, $7.479m to $0.602m. That $6.877m fall is 84% of the $8.220m rise in operating profit.
- THE PROOF: G&A fell $4.670m in total, but the stock compensation inside it fell $5.265m - so every other administrative cost actually rose.
- THE BANK: financial income $10.556m vs operating profit $9.308m - 1.13x. Interest is 56.0% of pre-tax profit, and it fell 13.4% across the half.
- THE CASH: operating cash flow $18.2m to $6.2m, down 66.1%. Inventory $30.9m to $63.8m (70 to 124 days); fixed assets $15.7m to $35.0m.
- THE COUNTER: revenue +16.0% and accelerating four quarters running. Strip the cash out and the enterprise is $127m - just 4.2x non-GAAP operating profit.
- THE BOOK: $976.1m of cash and ZERO borrowings against a $1,103m market value. Net cash is $1.58 of the $1.79 share price - 88% of it.
- THE CALL: HOLD 3/5, fair value $1.94 vs $1.79 (+8.4%): cash at a 20% haircut plus 16x after-tax operating profit. Bull $2.62, bear $1.39. The only live Street target is $3.69 (Jefferies, 3 March 2026, set 175 days before this print).
What to watch: UP: revenue growth accelerating for a fourth straight quarter, +1.2%, +3.4%, +8.3%, +16.0%; PaaS revenue $67.9m, up 16.9%; non-GAAP operating profit up 11.7% to $9.6m; ZERO interest-bearing borrowings; $976.1m of cash, deposits and treasuries against a ~$1,103m market value, so an enterprise value of only ~$127m, or 4.2x trailing non-GAAP operating profit and 0.37x trailing revenue; premium PaaS customers 285 to 318; a $37.0m dividend paid in April. DOWN: non-GAAP net profit fell 5.8% and non-GAAP net margin went 25.1% to 20.4%; gross margin fell 2.0 points to 46.3% so gross profit grew only 11.1%; operating cash flow fell 66.1% to $6.2m as inventory doubled from $30.9m to $63.8m (70 to 124 days) and fixed assets doubled to $35.0m; interest income fell 13.4% across the half as the pile went $1,017.3m to $976.1m; no buyback and the diluted share count rose 0.97%.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

SFL Corporation Ltd. (SFL) Q2 2026 — Q2 2026 (three months ended June 30, 2026): total operating revenues $200.8m vs $174.5m in Q1; net income $33.8m; basic and diluted EPS $0.25 vs a $0.14 consensus bar; adjusted EBITDA $129.9m including $7.8m from associates, up 19.9% on the quarter; 90th consecutive quarterly dividend of $0.22. Shares closed August 26 at $12.03, down 1.55% from $12.22 on 2,339,022 shares.
SFL Corporation beat on both lines: EPS $0.25 against a $0.14 bar and revenue $200.8m against $179.7m expected, with adjusted EBITDA up 19.9% sequentially to $129.9m. The stock opened higher, ran to $12.75 intraday, then closed down 1.55% at $12.03. The reason is in the six-month interim report rather than the press release. SFL sells a $3.8bn fixed-rate charter backlog with 6.2 years of weighted term - and contracted TIME CHARTER revenue, the line that backlog actually describes, fell 13.8% year on year, from $312.5m to $269.4m. A $43.1m hole. Total revenue barely moved because VOYAGE CHARTER AND POOL revenue - the spot line, in no backlog, repriced every voyage - went from $9.4m to $46.3m and filled 86% of it. Two Suezmax tankers earning $133,000 a day did that.
THE CALL: HOLD (3/5, A REAL BEAT DELIVERED BY THE QUARTER OF THE FLEET THAT IS IN NO BACKLOG) — base-case value ~$10.26 vs ~$12.03 today.
KEY METRICS:
- THE SPINE: six-month contracted time charter revenue fell 13.8%, $312.5m to $269.4m - a $43.1m hole in the one line the $3.8bn backlog describes.
- THE FILL: spot voyage and pool revenue rose 4.9x, $9.4m to $46.3m, covering 86% of that hole. Total six-month revenue moved just -1.1%.
- THE RATE: two Suezmax tankers averaged $133,000/day spot TCE; two Kamsarmax bulkers $16,000/day. Tanker charter hire jumped $16m on fewer operating days.
- THE RIGS: Energy took $24.3m of revenue to $1.1m of adjusted EBITDA (4.7%) and a $19.3m net loss at 50% utilisation. Shipping: $176.5m to $121.0m (68.6%).
- THE BRIDGE: Shipping earned $0.39/sh and Energy handed back $0.14/sh, to the filed $0.25. Basis proved: Q1 $0.20 + Q2 $0.25 = the filed half-year $0.45.
- THE BOOK: net debt $2,271m vs a $1,668m market value; EV $3,940m = 8.38x normalised adjusted EBITDA of $470m; book value $7.47/sh, so 1.61x.
- THE CALL: HOLD 3/5, fair value $10.26 vs $12.03 (-14.7%). An 8.0x asset multiple gives $10.74 and a dividend discount on $0.88 gives $9.78. Bull $14.17, bear $5.91.
What to watch: UP: a genuine beat on both lines; adjusted EBITDA +19.9% sequentially; a 68.6% Shipping segment adjusted EBITDA margin; 65% of the backlog to investment grade counterparties over 6.2 years; the 90th consecutive dividend, covered 1.14x by earnings and 2.97x by operating cash flow; $273m of liquidity after redeeming a $150m bond and tapping $78m more at a 6.8% implied yield. DOWN: contracted time charter revenue -13.8% year on year; the spot line that replaced it is four vessels and a $133k/day rate that does not annualise; the Energy segment turned $24.3m of revenue into $1.1m of adjusted EBITDA and a $19.3m net loss at 50% utilisation; net debt of $2,271m against a market value of $1,668m; the share count rose 4.27% in one quarter; first newbuild delivery is 2028.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Citi Trends, Inc. (CTRN) Q2 FY2026 — Q2 FY2026 (thirteen weeks ended August 1, 2026): net sales $211.632m vs $190.750m; comps +10.5%; gross margin 40.6% vs 40.0%; operating loss $1.707m vs income of $3.517m; net loss $0.931m vs income of $3.818m; EPS -$0.11 vs $0.48 basic. Released before the open on Tuesday Aug 25 (8-K accepted 06:52 ET). The shares gapped -12.07% to $65.38, made that the day's low, and closed $69.71, -6.24%, on 6.8x the twelve-month median volume.
Citi Trends posted its eighth consecutive quarter of comparable store sales growth: comps +10.5%, sales up 10.9% to $211.6m, gross margin 60bp wider, adjusted SG&A leveraged 260bp. The shares opened 12.07% lower. Two reasons. The sales line was already public - pre-announced on August 10, fifteen days early - and store capital spending has gone $10.1m to $22.7m to a guided $35m-$40m, which is 93.8% of the $38m-$42m of adjusted EBITDA those stores are meant to earn.
THE CALL: HOLD (3/5, A REAL EIGHT-QUARTER TURNAROUND WHOSE PROFIT IS ALREADY SPOKEN FOR) — base-case value ~$58.67 vs ~$69.71 today.
KEY METRICS:
- THE SPINE: capital expenditure went $10.108m in FY2024 to $22.7m in FY2025 to a guided $35m-$40m in FY2026 - 3.71x in two years. Against a guided $38m-$42m of adjusted EBITDA that is 93.8% at the midpoints; FY2025 was 132.1%. Cumulatively the stores have cost $60.2m and produced $57.2m - the store bill runs $3.0m AHEAD of the profit it exists to create.
- SO FREE CASH FLOW IS NEGATIVE ON THE COMPANY'S OWN TWO GUIDED RANGES: $40.0m of adjusted EBITDA, less the $5.75m of equity compensation that measure adds back, less $37.5m of capital expenditure = -$3.25m, before working capital and before any cash tax.
- AND MANAGEMENT REALLOCATED INSIDE IT: new stores CUT from 25 to 20, remodels RAISED from 50 to 60-65, the capital line left unchanged. At that pace 594 stores cycle every 9.5 years - a running cost, not a project. 26 remodels were done in the quarter, 51 in the half.
- THE SALES WERE PUBLISHED 15 DAYS EARLY: on August 10 the company pre-announced Q2 sales of $211.6m and comps of +10.5% at an investor conference. It filed $211.632m on the 25th. The stock traded to $77.91 that day - its twelve-month high - and set its highest close, $76.18, the next session.
- THE PRIOR YEAR'S PROFIT WAS A BUILDING: Q2 FY2025 net income of $3.818m included an $11.0m gain on the sale of the Savannah office building - 287% of the whole of it. Ex-gain the comparative operating line was -$7.443m, so the merchandise business improved $5.7m in a quarter in which the printed line fell $5.2m.
- THE BUYBACK STOPPED AND A SHELF ARRIVED: $6.315m (250,555 shares) repurchased in the Feb-May 2025 quarter and nothing in the five since, with $40.0m still authorised. The weighted share count ROSE 1.87%. At 08:39 ET on print day - 51 minutes before the open - a $100,000,000 Form S-3, 17.2% of the market value, the first since 2007.
- THE STREET: only TWO sell-side targets could be sourced AND dated in all of 2026 - D.A. Davidson (Michael Baker) Buy $81 on Aug 26, and Craig-Hallum Buy $67 dated Mar 17, which pre-dates both quarters of this fiscal year. We value CTRN at $58.67 against $69.71: HOLD, 3/5. Bull $86.45, bear $32.30.
What to watch: UP: eight straight quarters of comps, +19.7% two-year; a 46.0% incremental gross margin and 31.6% flow-through to adjusted EBITDA; guidance raised a third time; no debt and $55.9m of cash. DOWN: guided free cash flow of -$3.25m; two years of capex ($60.2m) exceeding two years of adjusted EBITDA ($57.2m); a $100m shelf filed 51 minutes before the open, the first since 2007; short interest 11.7% of float.
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.